ZBH ZIMMER BIOMET HOLDINGS, INC.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1136869 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.0%
TTM net income YoY-4.7%
TTM EPS YoY-1.7%
Revenue 3-yr CAGR5.6%
Net income 3-yr CAGR17.4%
Margins
Gross margin69.7%
Operating margin13.6%
Net margin9.0%
FCF margin19.2%
EBITDA margin26.5%
Returns
ROE6.0%
ROA3.3%
ROIC (approx.)5.1%
Asset turnover0.36x
Leverage & solvency
Liabilities / assets45.9%
Debt / equity0.59x
Current ratio1.46x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.46x
Accruals ratio-4.8%
Payout ratio24.3%
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $8.23B | $7.68B |
| Cost of revenue | $2.49B | $2.19B |
| Gross profit | $5.74B | $5.49B |
| R&D expense | $458.50M | $437.40M |
| SG&A expense | $3.26B | $2.93B |
| Operating income | $1.10B | $1.29B |
| Pretax income | $830.80M | $1.04B |
| Income tax | $125.70M | $131.40M |
| Net income | $705.10M | $903.80M |
| EBITDA | $2.19B | $2.28B |
| EPS (basic) | 3.56 | 4.45 |
| EPS (diluted) | 3.55 | 4.43 |
| Dividends declared per share | 0.96 | 0.96 |
| Weighted avg. shares (diluted) | 198.70M | 203.90M |
| Banking | ||
| Net interest income | -$292.80M | -$218.00M |
| Balance sheet | ||
| Cash & equivalents | $591.90M | $525.50M |
| Receivables | $1.70B | $1.48B |
| Inventory | $2.29B | $2.24B |
| Current assets | $5.12B | $4.67B |
| PP&E, net | $2.21B | $2.05B |
| Goodwill | $9.95B | $8.95B |
| Intangibles | $4.72B | $4.60B |
| Total assets | $23.09B | $21.37B |
| Current liabilities | $2.58B | $2.45B |
| Short-term debt | $587.10M | $863.00M |
| Long-term debt | $6.93B | $5.34B |
| Total debt | $7.52B | $6.20B |
| Total liabilities | $10.39B | $8.89B |
| Shareholders' equity | $12.70B | $12.47B |
| Net debt | $6.93B | $5.68B |
| Cash flow statement | ||
| Operating cash flow | $1.70B | $1.50B |
| Capital expenditure | $224.50M | $203.80M |
| Free cash flow | $1.47B | $1.30B |
| Investing cash flow | -$1.98B | -$888.10M |
| Financing cash flow | $326.00M | -$484.50M |
| Depreciation & amortization | $1.09B | $996.30M |
| Stock-based compensation | $90.20M | $101.00M |
| Dividends paid | $190.30M | $196.00M |
| Share buybacks | $487.00M | $868.00M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.